Castle Biosciences (CSTL) Operating Expenses (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Operating Expenses data on file, last reported at $102.1 million in Q1 2026.

• Quarterly Operating Expenses fell 11.93% year-over-year to $102.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $373.2 million (up 3.42% YoY) and the FY2025 annual result came in at $387.0 million, up 19.68% from the prior year.
• Operating Expenses climbed to $102.1 million in Q1 2026 per CSTL's latest filing, from $90.8 million in the prior quarter.
• The five-year high for Operating Expenses was $115.9 million in Q1 2025, with the low at $38.8 million in Q2 2022.
• Average Operating Expenses over 5 years is $77.1 million, with a median of $78.4 million recorded in 2024.
• Year-over-year, Operating Expenses surged 113.42% in 2022 and fell 11.93% in 2026.
• Castle Biosciences' Operating Expenses stood at $61.2 million in 2022, then increased by 17.34% to $71.8 million in 2023, then rose by 14.6% to $82.3 million in 2024, then increased by 10.43% to $90.8 million in 2025, then advanced by 12.38% to $102.1 million in 2026.
• Business Quant data shows CSTL's Operating Expenses at $102.1 million in Q1 2026, $90.8 million in Q4 2025, and $89.8 million in Q3 2025.